DailyIQ
|
DailyIQ
|
Sector:HealthcareAll sectors
Last updatedUpdating…

AZN·Astrazeneca PLC

$186.49
-0.36 (-0.19%)
High
$186.77
Open
$181.35
Market Cap
217.50B
52W High
$212.82
Low
$180.37
P. Close
$186.49
P/E
26.54
52W Low
$153.41
Fwd P/E
16.51
DailyIQ Est.
$215.18
Inst. Own.
35.2%
Short Interest
0.28%
Days to Cover
1.1
Div. Yield
1.16%
Last Ex-Div
Feb 19, 2026
Technical Score (1D)
50
NEUTRAL
News Sentiment
55
BULLISH
On Nov 5, a market study projected the global antibody‑drug conjugate market to reach $74.15 billion by 2036, citing a 13.5 % CAGR driven by oncology demand, label expansion and the rise of next‑generation ADCs, especially in the Asia‑Pacific region; the report noted AstraZeneca as one of the active manufacturers. On the same day, AstraZeneca CEO Pascal Soriot said that artificial intelligence alone cannot cure diseases, noting that no AI‑designed drug has yet received FDA clearance and that AI mainly assists in target selection and patient identification. Also on Nov 5, AstraZeneca completed a $2 billion strategic equity investment in Summit Therapeutics to support the ivonescimab clinical program, following Summit’s Q3 earnings that showed a narrower loss per share than expected and a significant increase in R&D spending on the ivonescimab studies. The capital infusion was reported to strengthen Summit’s cash position and enable continued development of ivonescimab, which has no marketed product yet. In addition, a dividend analysis on Nov 5 highlighted that AstraZeneca achieved a 2.3 % dividend yield within a quality screen, underscoring its strong profitability and solid financial health while noting minor liquidity concerns.
LOW TARGET
$158 -15.3%
2 analysts
MEAN TARGET
$207 +10.8%
17 analysts
HIGH TARGET
$240 +28.7%
17 analysts
PRICE RANGE
$158.00 - $240.00
SB / B / H / S / SS
12/16/6/1/1
DAILYIQ EST.
$215.18 (+15.4%)
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NMS
Country
United Kingdom
Website
astrazeneca.com
Symbol
AZN
Description
AstraZeneca PLC is a biopharmaceutical company specializing in the research, development, production, and marketing of prescription medications. Its diverse portfolio of products addresses a wide range of therapeutic areas, including oncology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune therapies, and rare diseases. AstraZeneca's commercialization strategy involves distribution and direct engagement with healthcare professionals across key markets like the United Kingdom, the United States, Europe, and Asia. The company strategically partners with other entities, such as Tempus, IonQ, and CSPC Pharmaceutical Group Limited, to advance its research and development initiatives, particularly in oncology and computational chemistry. Originally incorporated in 1992 and headquartered in Cambridge, UK, AstraZeneca has evolved from its prior name, Zeneca Group PLC.
Bought (1Y)
20.233 shares
$3K
Sold (1Y)
0 shares
$0
Sharma ManiSee remarks
Award/Grant2 shares2026-10-06
Sharma ManiSee Remarks
Award/Grant1 shares2026-09-08
Sharma ManiSee Remarks
Buy20.233 shares2026-08-08
Sharma ManiSVP, Group Controller
Award/Grant2 shares2026-08-06
Sharma ManiSee Remarks
Award/Grant2 shares2026-07-06
View full insider trading history →
Earnings Summary
In the most recent quarters, Q3 2026 revenue rose 7 % to $16.21 billion, while core EPS increased 14 % to $2.08, reflecting operational leverage and higher‑margin sales; this compares to Q2 2026 revenue of $15.38 billion and EPS of $1.315, indicating a slight revenue deceleration but a stronger EPS performance. AstraZeneca has consistently beat estimates in recent quarters, with EPS exceeding forecasts in Q4 2024, Q1 2025, Q3 2025, Q1 2026, and Q2 2026, though Q2 2025 EPS fell short of expectations. Historically, the company has maintained steady YoY revenue growth, with oncology driving a 16 % increase in Q3 2026 and a 32 % rise in alliance revenue from key assets such as Enhertu, Datroway, and Tezspire. Despite occasional EPS misses, revenue growth has remained robust, underscoring a pattern of strong top‑line performance even when earnings lag. Recent news highlights include the termination of the Phase III AWAKE trial for Ultomiris, a setback in pipeline diversification, and the launch of a $1.5 billion annual savings plan to fund AI‑driven drug development, alongside a $2 billion restructuring cost ceiling. These initiatives reinforce AstraZeneca’s focus on oncology and cost predictability.

EPS

EstBeatMiss
$0.93$1.08$1.23$1.38$1.53Q2'25Q3'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.15$1.00-12.7%
Q2'26$1.25$1.31+4.9%
Q1'26$1.27$1.29+1.4%
Q3'25$1.13$1.19+4.9%
Q2'25$1.46$1.08-25.9%

Revenue

EstBeatMiss
$14.1B$14.8B$15.6B$16.3B$17.0BQ2'25Q3'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$16.7B$16.2B-2.7%
Q2'26$16.0B$15.4B-4.1%
Q1'26$15.4B$15.3B-0.5%
Q3'25 - $15.2B -
Q2'25 - $14.5B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

AZN Stock Snapshot

NEUTRAL50/100
$186.49−$0.36 (0.2%)
Market cap
217.50B
P/E ratio
26.5
Day range
$180.37 – $186.77
News sentiment
55/100 · Neutral
Analyst target
$206.66 (+10.8%)
Consensus
Buy · 36 analysts
52-week range+21.6% off low · -12.4% from high
$153.41$212.82
Price $186.49 DailyIQ Est. $215.18

AZN ranks mid-pack on momentum, neither leading nor lagging its peers by much. Coverage is deep enough that new information gets priced quickly, so surprises tend to be macro rather than fundamental.

Sector Rotation

Is money rotating into or out of AZN's sector?

Astrazeneca PLC sits in the Health Care sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (weakening).

Sector rank
#1 of 12
Sector state
Weakening
Sector rotation score
100

Options Market

What is the options market pricing for AZN?

CallsPuts

For Astrazeneca PLC's nearest expiry (2026-11-20, 14 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.59), with at-the-money implied volatility around 30.1%. The options market is pricing roughly a ±5.7% move by that expiry — a range of about $175.88–$197.08.

Put/call ratio (2026-11-20)
0.59
ATM implied volatility
30.1%
Total open interest
15,337
Expected move by 2026-11-20
±5.7% ($175.88–$197.08)

Analyst Consensus Estimates

What do analysts expect AZN to earn?

Analysts expect Astrazeneca PLC to earn $10.16 per share in the fiscal year ending Dec 2026 and $11.99 in the fiscal year ending Dec 2028, from 3 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.

Quarter endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Dec 2026$1.61$1.61 to $1.611$16.65B13
Mar 2027$2.76$2.60 to $2.922$15.97B2
Jun 2027$2.83$2.73 to $2.932~$16.78B-
Sep 2027$2.96$2.91 to $3.002~$17.55B-
Fiscal year endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Dec 2026$10.16$10.16 to $10.161$63.33B25
Dec 2027$11.32$10.84 to $11.843$67.30B24
Dec 2028$11.99$11.52 to $12.333~$71.09B-

Revenue marked ~ is our calculation from the EPS estimate, not analyst consensus.

Analyst Rating Changes

Are analysts turning bullish or bearish on AZN?

CICC most recently initiated coverage on Astrazeneca PLC to Outperform on Aug 24, 2026 with a price target of $198. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
CICC: Outperform
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Aug 24, 2026CICCInitiatedOutperform$198
Feb 13, 2025UBSUpgradeNeutral → Buy-
Nov 20, 2024UBSUpgradeSell → Neutral-
Sep 11, 2024Erste GroupUpgradeHold → Buy-
Aug 12, 2024TD CowenMaintainedBuy$90 → $95
May 30, 2024Argus ResearchMaintainedBuy$80 → $85
May 30, 2024Goldman SachsInitiatedBuy$97
Apr 26, 2024BMO CapitalMaintainedOutperform$80 → $82
Apr 16, 2024Deutsche BankUpgradeSell → Hold-
Feb 12, 2024BMO CapitalMaintainedOutperform$82 → $80
Feb 8, 2024Deutsche BankDowngradeBuy → Hold-
Jan 23, 2024Morgan StanleyInitiatedOverweight$85

Peers & ETF holders

AZN peers & ETF holders

Drug Manufacturers - GeneralMarket cap · today

Top ETF holdersWeight

News & sentiment

What is the news saying about AZN?

AZN rose 17.3% over the month to Nov 6. News tone held between 45 and 81 from Oct 6 to Nov 5, then dropped to 12 on Nov 6.

Daily close and news tone, Oct 6 to Nov 6
$160$180Oct 6: tone 81Oct 7: tone 58Oct 8: tone 76Oct 9Oct 12: tone 60Oct 13: tone 64Oct 14: tone 54Oct 15: tone 74Oct 16: tone 59Oct 19: tone 59Oct 20: tone 70Oct 21: tone 74Oct 22: tone 69Oct 23Oct 26: tone 66Oct 27: tone 65Oct 28: tone 56Oct 29: tone 45Oct 30: tone 72Nov 2: tone 51Nov 3: tone 50Nov 4: tone 67Nov 5: tone 50Nov 6: tone 12Oct 6News toneNov 6123
  1. Oct 14 +3.7%
  2. Oct 15 +3.1%same day: insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies
  3. Oct 30 +6.5%same day: AstraZeneca holds guidance as cancer drugs outrun the Farxiga generics hit
Latest stories naming AstraZeneca

Technical analysis

How strong is AZN's momentum right now?

On the daily chart AZN ranks at the 50th percentile for momentum against the stocks and ETFs DailyIQ tracks, a neutral reading.

Momentum rank by timeframe0 = weakest, 100 = strongest
See what drives the rankThe inputs behind each timeframe's momentum rank, plus RSI, stochastics, Bollinger Bands and moving averages. Free with an account.

Institutional ownership

Are big funds buying or selling AZN?

66 of the 143 tracked managers added to AZN in their latest 13F and 71 trimmed. Together they own 35.2% of the company, worth $79.1B. Vanguard Capital Management and Capital International Investors alone hold 6.9%.

66adding71trimming6unchanged
Largest holders by stake, latest 13FBar = share of AZN
  1. 1Vanguard Capital Management LLC3.89%
    $8.5B positionAdded 0.8% last quarter
  2. 2Capital International Investors2.96%
    $6.5B positionAdded 0.5% last quarter
  3. 3Legal & General Group Plc2.21%
    $4.8B positionTrimmed 0.4% last quarter
  4. 4Vanguard Asset Management, Ltd1.60%
    $3.5B positionAdded 1.0% last quarter
  5. 5PRIMECAP Management Co1.55%
    $3.4B positionTrimmed 0.7% last quarter
  6. 6Franklin Resources Inc (Franklin Templeton)1.42%
    $3.1B positionTrimmed 7.2% last quarter
  7. 7Amundi1.41%
    $3.1B positionAdded 6.7% last quarter
  8. 8Vanguard Fiduciary Trust Co1.14%
    $2.5B positionAdded 0.7% last quarter
  9. 9Deutsche Bank AG1.08%
    $2.4B positionAdded 4.2% last quarter
  10. 10DZ Bank AG1.00%
    $2.2B positionTrimmed 9.4% last quarter
Full holdings history

Congressional trading

Is Congress trading AZN?

7 members of Congress disclosed 18 AZN trades between Sep 8, 2017 and Mar 31, 2026: 12 buys and 6 sells, about $168.5K in estimated value.

BuysSells20182020202220242026
BuySell$1K–$15K$15K–$50K$50K–$100K$100K–$250K

What stands out

Click one to highlight its trades in the chart
Full trading history

Discover more

How has AZN done against its peers?

Over the six months to Nov 6, AZN returned +0.8%. Of the 15 related stocks and ETFs, all did better, led by TMO at +46.8%.

Change since May 6, through Nov 6
−40%−20%0%+20%+40%+60%May 6JunJulAugSepOctNov 6TMO +46.8%AZN +0.8%